Redafamdastat

Clinical data
Other names	JZP-150; JZP150; PF-04457845; PF-4457845; PF04457845; PF4457845
Routes of administration	By mouth
ATC code	None
Legal status
Legal status	US: Investigational New Drug
Pharmacokinetic data
Metabolism	CY3A4
Identifiers
IUPAC name N-pyridazin-3-yl-4-[(3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl)methylidene]piperidine-1-carboxamide
CAS Number	1020315-31-4 Y
PubChem CID	24771824
ChemSpider	26390839
UNII	H4C81M8YYW
ChEMBL	ChEMBL1651534
CompTox Dashboard (EPA)	DTXSID00144539
Chemical and physical data
Formula	C23H20F3N5O2
Molar mass	455.441 g·mol−1
3D model (JSmol)	Interactive image
SMILES n4ncccc4NC(=O)N(CC3)CC\C3=C/c2cc(ccc2)Oc(cc1)ncc1C(F)(F)F
InChI InChI=1S/C23H20F3N5O2/c24-23(25,26)18-6-7-21(27-15-18)33-19-4-1-3-17(14-19)13-16-8-11-31(12-9-16)22(32)29-20-5-2-10-28-30-20/h1-7,10,13-15H,8-9,11-12H2,(H,29,30,32) Key:BATCTBJIJJEPHM-UHFFFAOYSA-N

Redafamdastat (INNTooltip International Nonproprietary Name; developmental code names JZP-150, PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀Tooltip half-maximal inhibitory concentration of 7.2 nM, and both analgesic and anti-inflammatory effects in animal studies comparable to those of the cyclooxygenase inhibitor naproxen.^[1] It was being developed by Jazz Pharmaceuticals for the treatment of alcoholism, pain, and post-traumatic stress disorder (PTSD) and reached phase 2 clinical trials.^[3] However, development of the drug was discontinued in December 2023.

• 4-Nonylphenylboronic acid
• LY-2183240
• EX-597
• BIA 10-2474